Under the leadership of investigators with a wide range of interests including clinical and basic research in BPH and prostate cancer, clinical trials recruitment and management, minority health issues, and geriatric medicine, Baylor proposes to establish a Clinical Center which will work cooperatively with the other clinical centers participating in this clinical trial, the data coordinating center, the diagnostic center, and the NIDDK Project Coordinator to develop and implement a full scale, common protocol for subject recruitment and screening, medical therapy intervention, patient monitoring and follow-up, and data and specimen collection and management. Drawing from a potential recruitment population of over 7200 men over the age of 50 with an AUA symptom score equal to or greater than 8, the Baylor Clinical Center pledges with reasonable assurance to randomize 200 patients on this clinical trial within a 24 month period, and follow them for a period of up to six years. The Baylor Clinical Center offers a unique opportunity to recruit a significant number of minority and geriatric subjects to this trial due to the unique resources committed to its execution. Our center also has significant resources committed to a care of young investigators who are poised to propose and carry out novel basic research studies into the pathogenesis and therapy of BPH as an adjunct to this clinical trial. Though maintaining a separate organizational structure and budget, the Baylor Clinical Center will draw from the significant experience and expertise in the areas of large scale patient data management, information systems, and tissue and serum banking acquired as a consequence of the Baylor SPORE in prostate cancer. Through the efforts of this RFA proposal, the Baylor Clinical Center along with the other centers and the NIDDK hopes to answer important questions regarding the ability of medical therapy to impact on the progression of BPH and to gain insights into the clinical, pathological, and molecular correlates to disease response and progression.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Kusek, John W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Schools of Medicine
United States
Zip Code
Kaplan, Steven A; Lee, Jeannette Y; O'Neill, Edward A et al. (2013) Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male 16:169-72
Kaplan, Steven A; Lee, Jeannette Y; Meehan, Alan G et al. (2011) Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol 185:1369-73
Kaplan, Steven A; Roehrborn, Claus G; McConnell, John D et al. (2008) Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol 180:1030-2;discussion 1032-3
Johnson 2nd, Theodore M; Burrows, Pamela K; Kusek, John W et al. (2007) The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 178:2045-50;discussion 2050-1
Crawford, E David; Wilson, Shandra S; McConnell, John D et al. (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175:1422-6; discussion 1426-7
Kaplan, Steven A; McConnell, John D; Roehrborn, Claus G et al. (2006) Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175:217-20; discussion 220-1
McConnell, John D; Roehrborn, Claus G; Bautista, Oliver M et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387-98